It was not to be, however: although the participants who received losmapimod, per the regimen shown in Table 1 , appeared to accumulate less fat in their muscles, achieve greater RWS, and gain more strength in their shoulder abductor muscles than those who were treated with placebo, these outcomes failed to reach statistical significance ( https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-topline-results-phase-3-reach ). 4.
← all excerpts
The recent clinical trial of losmapimod for the treatment of facioscapulohumeral muscular dystrophy.
1
—
—